ASCO-GU – Padcev and Keytruda impress again | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline
ASCO-GU – Padcev and Keytruda impress again | ApexOnco - Clinical Trials news and analysis Oncology Pipeline
Bladder Cancer News
Pfizer pulls EU filing for PD-1 inhibitor sasanlimab in bladder cancer - FirstWord Pharma
Pfizer pulls EU filing for PD-1 inhibitor sasanlimab in bladder cancer FirstWord Pharma
Padcev-Keytruda combo aces another bladder cancer trial as MIBC landscape becomes more complex - Fierce Pharma
Padcev-Keytruda combo aces another bladder cancer trial as MIBC landscape becomes more complex Fierce Pharma
ImmunityBio Trial Progress Puts Anktiva’s Global Cancer Potential in Focus - Yahoo Finance
ImmunityBio Trial Progress Puts Anktiva’s Global Cancer Potential in Focus Yahoo Finance
ASCO GU 2026: Are Combinatorial Therapies the Future Standard of Care in RCC and MIBC? - Cancer Therapy Advisor
ASCO GU 2026: Are Combinatorial Therapies the Future Standard of Care in RCC and MIBC? Cancer Therapy Advisor
Laura Bukavina, MD, MPH, MSc, outlines key considerations in wake of KEYNOTE-B15 data - Urology Times
Laura Bukavina, MD, MPH, MSc, outlines key considerations in wake of KEYNOTE-B15 data Urology Times
ImmunityBio Completes Enrollment in Pivotal Randomized Trial Evaluating ANKTIVA® Plus BCG Versus BCG Alone in BCG-Naïve Non-Muscle Invasive Bladder Cancer Carcinoma In Situ - Business Wire
ImmunityBio Completes Enrollment in Pivotal Randomized Trial Evaluating ANKTIVA® Plus BCG Versus BCG Alone in BCG-Naïve Non-Muscle Invasive Bladder Cancer Carcinoma In Situ Business Wire
Dr Necchi on Final Data From SunRISe-2 in Muscle-Invasive Bladder Cancer - OncLive
Dr Necchi on Final Data From SunRISe-2 in Muscle-Invasive Bladder Cancer OncLive
Blood Test Predicts Which Bladder Cancer Patients May Safely Skip Surgery - Fox Chase Cancer Center
Blood Test Predicts Which Bladder Cancer Patients May Safely Skip Surgery Fox Chase Cancer Center
2026 ASCO GU Highlights: Bladder Cancer KEYNOTE-B15 - Targeted Oncology
2026 ASCO GU Highlights: Bladder Cancer KEYNOTE-B15 Targeted Oncology
Padcev Plus Keytruda Improves Survival in Muscle-Invasive Bladder Cancer - CUREtoday.com
Padcev Plus Keytruda Improves Survival in Muscle-Invasive Bladder Cancer CUREtoday.com
RETAIN-2 Supports Response-Adapted Bladder Preservation in Muscle-invasive Bladder Cancer - HMP Global Learning Network
RETAIN-2 Supports Response-Adapted Bladder Preservation in Muscle-invasive Bladder Cancer HMP Global Learning Network
Can a New Testing Method Allow More Patients With Bladder Cancer to Avoid Radical Cystectomy - The ASCO Post
Can a New Testing Method Allow More Patients With Bladder Cancer to Avoid Radical Cystectomy The ASCO Post
Keytruda, Padcev combo cuts recurrence by 47% in earlier-stage bladder cancer - FirstWord Pharma
Keytruda, Padcev combo cuts recurrence by 47% in earlier-stage bladder cancer FirstWord Pharma
Padcev-Keytruda Combo Lands Another Win in Bladder Cancer - MedPage Today
Padcev-Keytruda Combo Lands Another Win in Bladder Cancer MedPage Today
Gemcitabine Intravesical System Plus Cetrelimab Misses the Mark in Muscle-Invasive Bladder Cancer - OncLive
Gemcitabine Intravesical System Plus Cetrelimab Misses the Mark in Muscle-Invasive Bladder Cancer OncLive
Combined Tests Could Reduce Unnecessary Bladder Removal - Fox Chase Cancer Center
Combined Tests Could Reduce Unnecessary Bladder Removal Fox Chase Cancer Center
Perioperative Enfortumab Vedotin Plus Pembrolizumab May Reduce Risk of Recurrence in Patients With Muscle-Invasive Bladder Cancer - The ASCO Post
Perioperative Enfortumab Vedotin Plus Pembrolizumab May Reduce Risk of Recurrence in Patients With Muscle-Invasive Bladder Cancer The ASCO Post
SWOG S1602: Tokyo BCG is noninferior to TICE in NMIBC - Urology Times
SWOG S1602: Tokyo BCG is noninferior to TICE in NMIBC Urology Times
Dr Thomas Powles on ctDNA Dynamics in the IMvigor011 Trial - Targeted Oncology
Dr Thomas Powles on ctDNA Dynamics in the IMvigor011 Trial Targeted Oncology
Poll Results Shed Light on Top Bladder, Kidney Cancer Abstracts to Watch at the 2026 Genitourinary Cancers Symposium - OncLive
Poll Results Shed Light on Top Bladder, Kidney Cancer Abstracts to Watch at the 2026 Genitourinary Cancers Symposium OncLive
Leslie Ballas, MD, highlights trial of risk-adapted bladder preservation in MIBC - Urology Times
Leslie Ballas, MD, highlights trial of risk-adapted bladder preservation in MIBC Urology Times
Protara sees 66% bladder cancer response rate at 6 months - Fierce Biotech
Protara sees 66% bladder cancer response rate at 6 months Fierce Biotech
Perioperative enfortumab vedotin + pembrolizumab tied to improved outcomes with bladder cancer - Medical Xpress
Perioperative enfortumab vedotin + pembrolizumab tied to improved outcomes with bladder cancer Medical Xpress
Robert S. Svatek, MD, outlines unmet needs in NMIBC - Urology Times
Robert S. Svatek, MD, outlines unmet needs in NMIBC Urology Times
Pooja Ghatalia, MD shares new insights from RETAIN trials in MIBC - Urology Times
Pooja Ghatalia, MD shares new insights from RETAIN trials in MIBC Urology Times
Bladder cancer combo cuts return risk nearly in half in major trial - Stock Titan
Bladder cancer combo cuts return risk nearly in half in major trial Stock Titan
Study finds link between colorblindness and death from bladder cancer - Stanford Medicine
Study finds link between colorblindness and death from bladder cancer Stanford Medicine
Enfortumab Vedotin Plus Pembrolizumab Improves Survival Outcomes While Preserving Surgical Feasibility - Pharmacy Times
Enfortumab Vedotin Plus Pembrolizumab Improves Survival Outcomes While Preserving Surgical Feasibility Pharmacy Times
Breakthrough in Bladder Cancer: The KEYNOTE-B15 Clinical Trial - Targeted Oncology
Breakthrough in Bladder Cancer: The KEYNOTE-B15 Clinical Trial Targeted Oncology
ASCO GU 2026 to Highlight the Latest Developments in Genitourinary Cancer - Cancer Therapy Advisor
ASCO GU 2026 to Highlight the Latest Developments in Genitourinary Cancer Cancer Therapy Advisor
Subgroup Analysis of SunRISE-2 - Targeted Oncology
Subgroup Analysis of SunRISE-2 Targeted Oncology
Tracey Emin on Love, Loss and Getting Out of ‘My Bed’ - The New York Times
Tracey Emin on Love, Loss and Getting Out of ‘My Bed’ The New York Times
Shilpa Gupta: Latest Advances in Bladder Cancer at ASCO GU 2026 - Oncodaily
Shilpa Gupta: Latest Advances in Bladder Cancer at ASCO GU 2026 Oncodaily
ImmVira's Oncolytic Product MVR-T3011 Expanded to BCG-Naïve Bladder Cancer Patients for the First Time with Clinical Data Presented at the 2026 ASCO GU Conference - PR Newswire
ImmVira's Oncolytic Product MVR-T3011 Expanded to BCG-Naïve Bladder Cancer Patients for the First Time with Clinical Data Presented at the 2026 ASCO GU Conference PR Newswire
ImmunityBio completes enrollment in bladder cancer trial - Investing.com
ImmunityBio completes enrollment in bladder cancer trial Investing.com
Combination Therapies Deliver Major Gains in Bladder and Kidney Cancer Survival - Mega Doctor News
Combination Therapies Deliver Major Gains in Bladder and Kidney Cancer Survival Mega Doctor News
ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer | New England Journal of Medicine - The New England Journal of Medicine
ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer | New England Journal of Medicine The New England Journal of Medicine
Meet the survivors, patients on CUOMO’s ‘Why Can’t We Cure Cancer’ special - NewsNation
Meet the survivors, patients on CUOMO’s ‘Why Can’t We Cure Cancer’ special NewsNation
Disitamab Vedotin Elicits Antitumor Activity in HER2-Expressing Advanced Urothelial Carcinoma - OncLive
Disitamab Vedotin Elicits Antitumor Activity in HER2-Expressing Advanced Urothelial Carcinoma OncLive